Targeting the Insulin Growth Factor Receptor 1

Hematology/Oncology Clinics of North America

Volumn 26, Issue 3, 2012, Pages 527-542

  Arnaldez, Fernanda I ^a   Helman, Lee J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cancer; IGF1; IGF1R; IGF2; Insulin; Kinase

Indexed keywords

ANTINEOPLASTIC AGENT; AVE 1642; AXL 1717; BMS 753807; CIXUTUMUMAB; DALOTUZUMAB; ENZYME INHIBITOR; FIGITUMUMAB; GANITUMAB; LINSITINIB; METFORMIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MEDI573; NORDIHYDROGUAIARETIC ACID; PEGVISOMANT; PICROPODOPHYLLIN; PODOPHYLLIN; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; ROBATUMUMAB; SOMATOMEDIN; SOMATOMEDIN C RECEPTOR; SOMATOSTATIN; TEPROTUMUMAB; UNCLASSIFIED DRUG; XL 228;

ACROMEGALY; ADRENAL CORTEX CARCINOMA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CEREBROVASCULAR ACCIDENT; CHOLESTASIS; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; COLORECTAL CARCINOMA; DESMOPLASTIC SMALL ROUND CELL TUMOR; DRUG SPECIFICITY; DRUG TARGETING; EWING SARCOMA; FATIGUE; GASTROINTESTINAL HEMORRHAGE; GLUCOSE BLOOD LEVEL; HEAD AND NECK CANCER; HEAD AND NECK CARCINOMA; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERSENSITIVITY; HYPERTENSION; HYPERURICEMIA; HYPOGLYCEMIA; INJECTION SITE REACTION; LIVER CELL CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPHOCYTOPENIA; MULTIPLE MYELOMA; NEOPLASM; NEUROENDOCRINE TUMOR; NONHUMAN; OSTEOSARCOMA; OVARY CANCER; OVARY CARCINOMA; PANCREAS CANCER; PANCREAS CARCINOMA; PANCREAS ISLET CELL CARCINOMA; PNEUMONIA; PRIORITY JOURNAL; PROSTATE CANCER; QT PROLONGATION; REVIEW; SIDE EFFECT; SOFT TISSUE SARCOMA; SOLID TUMOR; THROMBOCYTOPENIA; THYMUS CANCER;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; MOLECULAR TARGETED THERAPY; NEOPLASMS; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION;

EID: 84859979292     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2012.01.004     Document Type: Review

References (125)

1. Daughaday W.H., Hall K., Raben M.S., et al. Somatomedin: proposed designation for sulphation factor. Nature 1972, 235:107.
2. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008, 8:915-928.
3. Gallagher E.J., LeRoith D. Minireview: IGF, insulin, and cancer. Endocrinology 2011, 152:2546-2551.
4. Riedemann J., Macaulay V.M. IGF1R signalling and its inhibition. Endocr Relat Cancer 2006, 13(Suppl 1):S33-S43.
5. Pollak M. Insulin-like growth factor-related signaling and cancer development. Recent Results Cancer Res 2007, 174:49-53.
6. De Meyts P. Insulin and its receptor: structure, function and evolution. Bioessays 2004, 26:1351-1362.
7. Benyoucef S., Surinya K.H., Hadaschik D., et al. Characterization of insulin/IGF hybrid receptors: contributions of the insulin receptor L2 and Fn1 domains and the alternatively spliced exon 11 sequence to ligand binding and receptor activation. Biochem J 2007, 403:603-613.
8. Belfiore A. The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer. Curr Pharm Des 2007, 13:671-686.
9. Laube F. Mannose-6-phosphate/insulin-like growth factor-II receptor in human melanoma cells: effect of ligands and antibodies on the receptor expression. Anticancer Res 2009, 29:1383-1388.
10. Scott C.D., Firth S.M. The role of the M6P/IGF-II receptor in cancer: tumor suppression or garbage disposal?. Horm Metab Res 2004, 36:261-271.
11. Jeyaratnaganthan N., Hojlund K., Kroustrup J.P., et al. Circulating levels of insulin-like growth factor-II/mannose-6-phosphate receptor in obesity and type 2 diabetes. Growth Horm IGF Res 2010, 20:185-191.
12. Samani A.A., Yakar S., LeRoith D., et al. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 2007, 28:20-47.
13. Denley A., Bonython E.R., Booker G.W., et al. Structural determinants for high-affinity binding of insulin-like growth factor II to insulin receptor (IR)-A, the exon 11 minus isoform of the IR. Mol Endocrinol 2004, 18:2502-2512.
14. Favelyukis S., Till J.H., Hubbard S.R., et al. Structure and autoregulation of the insulin-like growth factor 1 receptor kinase. Nat Struct Biol 2001, 8:1058-1063.
15. Buck E., Mulvihill M. Small molecule inhibitors of the IGF-1R/IR axis for the treatment of cancer. Expert Opin Investig Drugs 2011, 20:605-621.
16. Shelton J.G., Steelman L.S., White E.R., et al. Synergy between PI3K/Akt and Raf/MEK/ERK pathways in IGF-1R mediated cell cycle progression and prevention of apoptosis in hematopoietic cells. Cell Cycle 2004, 3:372-379.
17. Levine A.J., Feng Z., Mak T.W., et al. Coordination and communication between the p53 and IGF-1-AKT-TOR signal transduction pathways. Genes Dev 2006, 20:267-275.
18. Pollak M.N. Insulin-like growth factors and neoplasia. Novartis Found Symp 2004, 262:84-98. [discussion: 98-107, 265-8].
19. Kim S.Y., Wan X., Helman L.J. Targeting IGF-1R in the treatment of sarcomas: past, present and future. Bull Cancer 2009, 96:E52-E60.
20. Amiel S.A., Sherwin R.S., Hintz R.L., et al. Effect of diabetes and its control on insulin-like growth factors in the young subject with type I diabetes. Diabetes 1984, 33:1175-1179.
21. Leung K.C., Doyle N., Ballesteros M., et al. Insulin regulation of human hepatic growth hormone receptors: divergent effects on biosynthesis and surface translocation. J Clin Endocrinol Metab 2000, 85:4712-4720.
22. Busund L.T., Ow K.T., Russell P., et al. Expression of insulin-like growth factor mitogenic signals in adult soft-tissue sarcomas: significant correlation with malignant potential. Virchows Arch 2004, 444:142-148.
23. Loeper S., Ezzat S. Acromegaly: re-thinking the cancer risk. Rev Endocr Metab Disord 2008, 9:41-58.
24. Steuerman R., Shevah O., Laron Z. Congenital IGF1 deficiency tends to confer protection against post-natal development of malignancies. Eur J Endocrinol 2011, 164:485-489.
25. Guevara-Aguirre J., Balasubramanian P., Guevara-Aguirre M., et al. Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans. Sci Transl Med 2011, 3:70ra13.
26. Wu Y., Cui K., Miyoshi K., et al. Reduced circulating insulin-like growth factor I levels delay the onset of chemically and genetically induced mammary tumors. Cancer Res 2003, 63:4384-4388.
27. LeRoith D., Roberts C.T. The insulin-like growth factor system and cancer. Cancer Lett 2003, 195:127-137.
28. Cui H., Cruz-Correa M., Giardiello F.M., et al. Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. Science 2003, 299:1753-1755.
29. Zhang L., Zhou W., Velculescu V.E., et al. Gene expression profiles in normal and cancer cells. Science 1997, 276:1268-1272.
30. Giordano T.J., Kuick R., Else T., et al. Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling. Clin Cancer Res 2009, 15:668-676.
31. Ravenel J.D., Broman K.W., Perlman E.J., et al. Loss of imprinting of insulin-like growth factor-II (IGF2) gene in distinguishing specific biologic subtypes of Wilms tumor. J Natl Cancer Inst 2001, 93:1698-1703.
32. Xu W., Fan H., He X., et al. LOI of IGF2 is associated with esophageal cancer and linked to methylation status of IGF2 DMR. J Exp Clin Cancer Res 2006, 25:543-547.
33. Zhan S., Shapiro D.N., Helman L.J. Loss of imprinting of IGF2 in Ewing's sarcoma. Oncogene 1995, 11:2503-2507.
34. Li Y., Meng G., Huang L., et al. Hypomethylation of the P3 promoter is associated with up-regulation of IGF2 expression in human osteosarcoma. Hum Pathol 2009, 40:1441-1447.
35. Fu V.X., Dobosy J.R., Desotelle J.A., et al. Aging and cancer-related loss of insulin-like growth factor 2 imprinting in the mouse and human prostate. Cancer Res 2008, 68:6797-6802.
36. Wu J., Qin Y., Li B., et al. Hypomethylated and hypermethylated profiles of H19DMR are associated with the aberrant imprinting of IGF2 and H19 in human hepatocellular carcinoma. Genomics 2008, 91:443-450.
37. Huynh H., Yang X., Pollak M. Estradiol and antiestrogens regulate a growth inhibitory insulin-like growth factor binding protein 3 autocrine loop in human breast cancer cells. J Biol Chem 1996, 271:1016-1021.
38. Gucev Z.S., Oh Y., Kelley K.M., et al. Insulin-like growth factor binding protein 3 mediates retinoic acid- and transforming growth factor beta2-induced growth inhibition in human breast cancer cells. Cancer Res 1996, 56:1545-1550.
39. Rozen F., Yang X.F., Huynh H., et al. Antiproliferative action of vitamin D-related compounds and insulin-like growth factor-binding protein 5 accumulation. J Natl Cancer Inst 1997, 89:652-656.
40. Buckbinder L., Talbott R., Velasco-Miguel S., et al. Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 1995, 377:646-649.
41. Duan C., Ren H., Gao S. Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins: roles in skeletal muscle growth and differentiation. Gen Comp Endocrinol 2010, 167:344-351.
42. Frystyk J., Vestbo E., Skjaerbaek C., et al. Free insulin-like growth factors in human obesity. Metabolism 1995, 44:37-44.
43. Grinspoon S., Clemmons D., Swearingen B., et al. Serum insulin-like growth factor-binding protein-3 levels in the diagnosis of acromegaly. J Clin Endocrinol Metab 1995, 80:927-932.
44. Prieur A., Tirode F., Cohen P., et al. EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol Cell Biol 2004, 24:7275-7283.
45. Werner H., Shen-Orr Z., Rauscher F.J., et al. Inhibition of cellular proliferation by the Wilms' tumor suppressor WT1 is associated with suppression of insulin-like growth factor I receptor gene expression. Mol Cell Biol 1995, 15:3516-3522.
46. Coughlin S.S., Calle E.E., Teras L.R., et al. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol 2004, 159:1160-1167.
47. Calle E.E., Rodriguez C., Walker-Thurmond K., et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003, 348:1625-1638.
48. Ahlgren M., Melbye M., Wohlfahrt J., et al. Growth patterns and the risk of breast cancer in women. N Engl J Med 2004, 351:1619-1626.
49. Chan J.M., Stampfer M.J., Giovannucci E., et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998, 279:563-566.
50. Diorio C., Pollak M., Byrne C., et al. Insulin-like growth factor-I, IGF-binding protein-3, and mammographic breast density. Cancer Epidemiol Biomarkers Prev 2005, 14:1065-1073.
51. Gualberto A., Pollak M. Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions. Oncogene 2009, 28:3009-3021.
52. All-Ericsson C., Girnita L., Seregard S., et al. Insulin-like growth factor-1 receptor in uveal melanoma: a predictor for metastatic disease and a potential therapeutic target. Invest Ophthalmol Vis Sci 2002, 43:1-8.
53. Hakam A., Yeatman T.J., Lu L., et al. Expression of insulin-like growth factor-1 receptor in human colorectal cancer. Hum Pathol 1999, 30:1128-1133.
54. Turner B.C., Haffty B.G., Narayanan L., et al. Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res 1997, 57:3079-3083.
55. Hellawell G.O., Turner G.D., Davies D.R., et al. Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Res 2002, 62:2942-2950.
56. Law J.H., Habibi G., Hu K., et al. Phosphorylated insulin-like growth factor-I/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res 2008, 68:10238-10246.
57. Badzio A., Wynes M.W., Dziadziuszko R., et al. Increased insulin-like growth factor 1 receptor protein expression and gene copy number in small cell lung cancer. J Thorac Oncol 2010, 5:1905-1911.
58. Bax D.A., Mackay A., Little S.E., et al. A distinct spectrum of copy number aberrations in pediatric high-grade gliomas. Clin Cancer Res 2010, 16:3368-3377.
59. Soroceanu L., Kharbanda S., Chen R., et al. Identification of IGF2 signaling through phosphoinositide-3-kinase regulatory subunit 3 as a growth-promoting axis in glioblastoma. Proc Natl Acad Sci U S A 2007, 104:3466-3471.
60. Belfiore A., Pandini G., Vella V., et al. Insulin/IGF-I hybrid receptors play a major role in IGF-I signaling in thyroid cancer. Biochimie 1999, 81:403-407.
61. Frasca F., Pandini G., Sciacca L., et al. The role of insulin receptors and IGF-I receptors in cancer and other diseases. Arch Physiol Biochem 2008, 114:23-37.
62. Sell C., Rubini M., Rubin R., et al. Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. Proc Natl Acad Sci U S A 1993, 90:11217-11221.
63. Martin M.J., Melnyk N., Pollard M., et al. The insulin-like growth factor I receptor is required for Akt activation and suppression of anoikis in cells transformed by the ETV6-NTRK3 chimeric tyrosine kinase. Mol Cell Biol 2006, 26:1754-1769.
64. Toretsky J.A., Kalebic T., Blakesley V., et al. The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts. J Biol Chem 1997, 272:30822-30827.
65. McKinsey E.L., Parrish J.K., Irwin A.E., et al. A novel oncogenic mechanism in Ewing sarcoma involving IGF pathway targeting by EWS/Fli1-regulated microRNAs. Oncogene 2011, 30(49):4910-4920.
66. Casa A.J., Dearth R.K., Litzenburger B.C., et al. The type I insulin-like growth factor receptor pathway: a key player in cancer therapeutic resistance. Front Biosci 2008, 13:3273-3287.
67. Ge J., Chen Z., Wu S., et al. Expression levels of insulin-like growth factor-1 and multidrug resistance-associated protein-1 indicate poor prognosis in patients with gastric cancer. Digestion 2009, 80:148-158.
68. Beech D.J., Parekh N., Pang Y. Insulin-like growth factor-I receptor antagonism results in increased cytotoxicity of breast cancer cells to doxorubicin and taxol. Oncol Rep 2001, 8:325-329.
69. Warshamana-Greene G.S., Litz J., Buchdunger E., et al. The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy. Clin Cancer Res 2005, 11:1563-1571.
70. D'Cunja J., Shalaby T., Rivera P., et al. Antisense treatment of IGF-IR induces apoptosis and enhances chemosensitivity in central nervous system atypical teratoid/rhabdoid tumours cells. Eur J Cancer 2007, 43:1581-1589.
71. Min Y., Adachi Y., Yamamoto H., et al. Insulin-like growth factor I receptor blockade enhances chemotherapy and radiation responses and inhibits tumour growth in human gastric cancer xenografts. Gut 2005, 54:591-600.
72. Luk F., Yu Y., Walsh W.R., et al. IGF1R-targeted therapy and its enhancement of doxorubicin chemosensitivity in human osteosarcoma cell lines. Cancer Invest 2011, 29:521-532.
73. Wang Y.H., Xiong J., Wang S.F., et al. Lentivirus-mediated shRNA targeting insulin-like growth factor-1 receptor (IGF-1R) enhances chemosensitivity of osteosarcoma cells in vitro and in vivo. Mol Cell Biochem 2010, 341:225-233.
74. Dallas N.A., Xia L., Fan F., et al. Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res 2009, 69:1951-1957.
75. Kai K., D'Costa S., Sills R.C., et al. Inhibition of the insulin-like growth factor 1 receptor pathway enhances the antitumor effect of cisplatin in human malignant mesothelioma cell lines. Cancer Lett 2009, 278:49-55.
76. Liu Y.C., Leu C.M., Wong F.H., et al. Autocrine stimulation by insulin-like growth factor I is involved in the growth, tumorigenicity and chemoresistance of human esophageal carcinoma cells. J Biomed Sci 2002, 9:665-674.
77. Chen M.Y., Clark A.J., Chan D.C., et al. Wilms' tumor 1 silencing decreases the viability and chemoresistance of glioblastoma cells in vitro: a potential role for IGF-1R de-repression. J Neurooncol 2011, 103:87-102.
78. Lee J.Y., Han C.Y., Yang J.W., et al. Induction of glutathione transferase in insulin-like growth factor type I receptor-overexpressed hepatoma cells. Mol Pharmacol 2007, 72:1082-1093.
79. Rochester M.A., Riedemann J., Hellawell G.O., et al. Silencing of the IGF1R gene enhances sensitivity to DNA-damaging agents in both PTEN wild-type and mutant human prostate cancer. Cancer Gene Ther 2005, 12:90-100.
80. Cosaceanu D., Budiu R.A., Carapancea M., et al. Ionizing radiation activates IGF-1R triggering a cytoprotective signaling by interfering with Ku-DNA binding and by modulating Ku86 expression via a p38 kinase-dependent mechanism. Oncogene 2007, 26:2423-2434.
81. Macaulay V.M., Salisbury A.J., Bohula E.A., et al. Downregulation of the type 1 insulin-like growth factor receptor in mouse melanoma cells is associated with enhanced radiosensitivity and impaired activation of Atm kinase. Oncogene 2001, 20:4029-4040.
82. Peretz S., Jensen R., Baserga R., et al. ATM-dependent expression of the insulin-like growth factor-I receptor in a pathway regulating radiation response. Proc Natl Acad Sci U S A 2001, 98:1676-1681.
83. Shahrabani-Gargir L., Pandita T.K., Werner H. Ataxia-telangiectasia mutated gene controls insulin-like growth factor I receptor gene expression in a deoxyribonucleic acid damage response pathway via mechanisms involving zinc-finger transcription factors Sp1 and WT1. Endocrinology 2004, 145:5679-5687.
84. Wakeling A.E., Nicholson R.I., Gee J.M. Prospects for combining hormonal and nonhormonal growth factor inhibition. Clin Cancer Res 2001, 7:4350s-4355s. [discussion: 4411s-2s].
85. Knowlden J.M., Hutcheson I.R., Barrow D., et al. Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor. Endocrinology 2005, 146:4609-4618.
86. Parisot J.P., Hu X.F., DeLuise M., et al. Altered expression of the IGF-1 receptor in a tamoxifen-resistant human breast cancer cell line. Br J Cancer 1999, 79:693-700.
87. Nicholson R.I., Gee J.M. Oestrogen and growth factor cross-talk and endocrine insensitivity and acquired resistance in breast cancer. Br J Cancer 2000, 82:501-513.
88. Cunningham M.P., Essapen S., Thomas H., et al. Coexpression of the IGF-IR, EGFR and HER-2 is common in colorectal cancer patients. Int J Oncol 2006, 28:329-335.
89. Mendelsohn J. The epidermal growth factor receptor as a target for cancer therapy. Endocr Relat Cancer 2001, 8:3-9.
90. Slamon D.J., Clark G.M., Wong S.G., et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182.
91. Press M.F., Bernstein L., Thomas P.A., et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 1997, 15:2894-2904.
92. Morgillo F., Woo J.K., Kim E.S., et al. Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. Cancer Res 2006, 66:10100-10111.
93. Morgillo F., Kim W.Y., Kim E.S., et al. Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib. Clin Cancer Res 2007, 13:2795-2803.
94. Lu Y., Zi X., Zhao Y., et al. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 2001, 93:1852-1857.
95. Balana M.E., Labriola L., Salatino M., et al. Activation of ErbB-2 via a hierarchical interaction between ErbB-2 and type I insulin-like growth factor receptor in mammary tumor cells. Oncogene 2001, 20:34-47.
96. Thankamony G.N., Dunger D.B., Acerini C.L. Pegvisomant: current and potential novel therapeutic applications. Expert Opin Biol Ther 2009, 9:1553-1563.
97. Dagnaes-Hansen F., Duan H., Rasmussen L.M., et al. Growth hormone receptor antagonist administration inhibits growth of human colorectal carcinoma in nude mice. Anticancer Res 2004, 24:3735-3742.
98. McCutcheon I.E., Flyvbjerg A., Hill H., et al. Antitumor activity of the growth hormone receptor antagonist pegvisomant against human meningiomas in nude mice. J Neurosurg 2001, 94:487-492.
99. Hejna M., Schmidinger M., Raderer M. The clinical role of somatostatin analogues as antineoplastic agents: much ado about nothing?. Ann Oncol 2002, 13:653-668.
100. Jerome L., Alami N., Belanger S., et al. Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo. Cancer Res 2006, 66:7245-7252.
101. Alami N., Page V., Yu Q., et al. Recombinant human insulin-like growth factor-binding protein 3 inhibits tumor growth and targets the Akt pathway in lung and colon cancer models. Growth Horm IGF Res 2008, 18:487-496.
102. Gao J., Chesebrough J.W., Cartlidge S.A., et al. Dual IGF-I/II-neutralizing antibody MEDI-573 potently inhibits IGF signaling and tumor growth. Cancer Res 2011, 71:1029-1040.
103. Schneider-Merck T., Lammerts van Bueren J.J., Berger S., et al. Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage. J Immunol 2010, 184:512-520.
104. Kurzrock R., Patnaik A., Aisner J., et al. A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors. Clin Cancer Res 2010, 16:2458-2465.
105. Pappo A.S., Patel S.R., Crowley J., et al. R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study. J Clin Oncol 2011, 29(34):4541-4547.
106. Tolcher A.W., Sarantopoulos J., Patnaik A., et al. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol 2009, 27:5800-5807.
107. Olmos D., Postel-Vinay S., Molife L.R., et al. Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. Lancet Oncol 2010, 11:129-135.
108. Pantaleo M.A., Astolfi A., Nannini M., et al. The emerging role of insulin-like growth factor 1 receptor (IGF1r) in gastrointestinal stromal tumors (GISTs). J Transl Med 2010, 8:117.
109. Braconi C., Bracci R., Cellerino R. Molecular targets in gastrointestinal stromal tumors (GIST) therapy. Curr Cancer Drug Targets 2008, 8:359-366.
110. Janeway K.A., Zhu M.J., Barretina J., et al. Strong expression of IGF1R in pediatric gastrointestinal stromal tumors without IGF1R genomic amplification. Int J Cancer 2010, 127:2718-2722.
111. Tarn C., Rink L., Merkel E., et al. Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors. Proc Natl Acad Sci U S A 2008, 105:8387-8392.
112. Jassem J., Langer C.J., Karp D.D., et al. Randomized, open label, phase III trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC). J Clin Oncol 2010, 28(Suppl; abstr 7500). Available at:, Accessed January 31, 2012. http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/7500.
113. Karp D.D., Paz-Ares L.G., Novello S., et al. Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol 2009, 27:2516-2522.
114. Buck E., Eyzaguirre A., Rosenfeld-Franklin M., et al. Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors. Cancer Res 2008, 68:8322-8332.
115. Guix M., Faber A.C., Wang S.E., et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest 2008, 118:2609-2619.
116. Wan X., Harkavy B., Shen N., et al. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 2007, 26:1932-1940.
117. Naing A., Kurzrock R., Burger A., et al. Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer. Clin Cancer Res 2011, 17:6052-6060.
118. Pollak M. Metformin and other biguanides in oncology: advancing the research agenda. Cancer Prev Res (Phila) 2010, 3:1060-1065.
119. Monami M., Colombi C., Balzi D., et al. Metformin and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care 2011, 34:129-131.
120. Chen T.M., Lin C.C., Huang P.T., et al. Metformin associated with lower mortality in diabetic patients with early stage hepatocellular carcinoma after radiofrequency ablation. J Gastroenterol Hepatol 2011, 26:858-865.
121. Bo S., Ciccone G., Rosato R., et al. Cancer mortality reduction and metformin. A retrospective cohort study in type 2 diabetic patients. Diabetes Obes Metab 2012, 14(1):23-29.
122. Jansen M., van Schaik F.M., Ricker A.T., et al. Sequence of cDNA encoding human insulin-like growth factor I precursor. Nature 1983, 306:609-611.
123. Heskamp S., van Laarhoven H.W., Molkenboer-Kuenen J.D., et al. ImmunoSPECT and immunoPET of IGF-1R expression with the radiolabeled antibody R1507 in a triple-negative breast cancer model. J Nucl Med 2010, 51:1565-1572.
124. Gualberto A., Pollak M. Clinical development of inhibitors of the insulin-like growth factor receptor in oncology. Curr Drug Targets 2009, 10:923-936.
125. Freude S., Schilbach K., Schubert M. The role of IGF-1 receptor and insulin receptor signaling for the pathogenesis of Alzheimer's disease: from model organisms to human disease. Curr Alzheimer Res 2009, 6:213-223.